annual meeting program - American Society of Clinical Oncology

Monday, June 7, 2010
Brd. 7 A double-blind, randomized, placebo-controlled phase III intergroup study of
gefitinib (G) in patients (pts) with advanced NSCLC, non-progressing after
first-line platinum-based chemotherapy (EORTC 08021-ILCP 01/03). (Abstract
#7518)
R. M. Gaafar, V. Surmont, G. Scagliotti, R. Van Klaveren, D. Papamichael,
J. Welch, B. Hasan, V. Torri, J. P. Van Meerbeeck
Brd. 8 Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with
advanced non-small cell lung cancer (NSCLC): Results of a randomized
phase III Hellenic Oncology Research Group trial. (Abstract #7519)
L. Vamvakas, S. Agelaki, N. K. Kentepozidis, A. Karampeazis, A. G. Pallis,
C. Christophyllakis, A. P. Kotsakis, I. Boukovinas, D. Mavroudis, V. Georgoulias
Brd. 9 Clinical course of patients (pts) with acquired resistance (AR) to EGFR
tyrosine kinase inhibitors (TKI). (Abstract #7520)
G. R. Oxnard, G. J. Riely, M. H. Arcila, M. G. Kris, W. Pao, M. Ladanyi, V. A. Miller
Brd. 10 A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung
and activating EGFR mutations (LUX-Lung 2). (Abstract #7521^)
C. Yang, J. Shih, W. Su, T. Hsia, C. Tsai, S. I. Ou, R. Calvo, X. J. Cong,
M. Shahidi, V. A. Miller
Brd. 11 Cetuximab for the treatment of advanced bronchioloalveolar carcinoma
(BAC): An Eastern Cooperative Oncology Group phase II study (ECOG 1504).
(Abstract #7522)
S. S. Ramalingam, J. Lee, C. P. Belani, S. C. Aisner, J. Kolesar, C. W. Howe,
M. R. Velasco, J. H. Schiller
Brd. 12 Efficacy and safety of PF299804 versus erlotinib (E): A global, randomized
phase II trial in patients (pts) with advanced non-small cell lung cancer
(NSCLC) after failure of chemotherapy (CT). (Abstract #LBA7523)
M. J. Boyer, F. H. Blackhall, K. Park, C. H. Barrios, M. J. Krzakowski, I. Taylor,
J. Q. Liang, L. J. Denis, J. P. O’Connell, S. S. Ramalingam
Brd. 13 Phase II study of everolimus plus erlotinib in previously treated patients with
advanced non-small cell lung cancer (NSCLC). (Abstract #7524)
N. B. Leighl, J. Soria, J. Bennouna, N. Blais, A. M. Traynor, V.
Papadimitrakopoulou, J. Klimovsky, A. Jappe, V. Jehl, B. E. Johnson
Brd. 14 Vandetanib versus placebo in patients with advanced non-small cell lung
cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor
(TKI): A randomized, double-blind phase III trial (ZEPHYR). (Abstract #7525)
J. Lee, V. Hirsh, K. Park, S. Qin, C. R. Blajman, R. Perng, L. Emerson,
P. B. Langmuir, C. Manegold
Brd. 15 Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B)
therapy with or without erlotinib (E) after completion of chemotherapy
(chemo) with B for first-line treatment of locally advanced, recurrent, or
metastatic non-small cell lung cancer (NSCLC). (Abstract #7526)
F. F. Kabbinavar, V. A. Miller, B. E. Johnson, P. G. O’Connor, C. Soh, ATLAS
Investigators
Brd. 16 A multicenter, randomized, double-blind, placebo-controlled study to
evaluate the clinical effects of paclitaxel-carboplatin (TC) alone or with
endostatin for advanced non-small cell lung cancer (NSCLC). (Abstract
#7527)
B. Han, Q. Xiu, Y. Luo, C. Bai, S. Guo, W. Liu, Z. Zhuang, Y. Zhang, J. Zhou, X. Jin
Brd. 17 Randomized, open-label phase II study of motesanib or bevacizumab in
combination with paclitaxel and carboplatin (P/C) for advanced
nonsquamous non-small cell lung cancer (NSCLC). (Abstract #7528)
G. R. Blumenschein, F. F. Kabbinavar, H. Menon, T. Mok, J. Stephenson,
J. T. Beck, K. Lakshmaiah, K. Kracht, R. S. Sikorski, L. S. Schwartzberg
339
MONDAY